


**Amendments to the Claims:**

Please amend claims 8, 16, 17 and 26,, as shown in the listing of claims that follows.  
This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-5 (canceled).

6. (Previously presented) A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome and Type II Diabetes, comprising administering to the subject an amount of a biologically active agent,  
wherein the agent is a compound of the formula:



Formula I

wherein

n is 1 or 2;

m is 0, 1, 2, 3 or 4;

q is 0 or 1;

t is 0 or 1;

R<sup>2</sup> is alkyl having from 1 to 3 carbon atoms;

R<sup>3</sup> is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or  
cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or  
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and


R<sup>1</sup> is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1, R<sup>1</sup> is not hydrogen;

or when R<sup>1</sup> is hydrogen, a pharmaceutically acceptable salt of the compound.

7. (Original) The method of claim 6, wherein n is 1; q is 0; t is 0; R<sup>3</sup> is hydrogen; and

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.

8. (Currently amended) The method of claim 7, wherein ~~wherein~~ A is 2,6-dimethylphenyl.
9. (Original) The method of claim 8, wherein the biologically active agent is 4-(3-(2,6-Dimethylbenzyloxy)-phenyl)-4-hydroxybutanoic acid.
10. (Original) The method of any one of claims 6 to 9, wherein the subject is a human.
11. (Original) The method of claim 10, wherein the agent is administered orally in an amount from one milligram to four hundred milligrams per day.
12. (Canceled)
13. (Previously presented) The method of claim 6, wherein the treatment reduces a symptom of diabetes or the chances of developing a symptom of diabetes, wherein the symptom is selected from the group consisting of: atherosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts, associated with diabetes.
14. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and from one milligram to four hundred milligrams of a biologically active agent, wherein the agent is a compound of the formula:



Formula I

wherein

n is 1 or 2;

m is 0, 1, 2, 3 or 4;

q is 0 or 1;

t is 0 or 1;

R<sup>2</sup> is alkyl having from 1 to 3 carbon atoms;

R<sup>3</sup> is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or  
 cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or

a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and

R<sup>1</sup> is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1, R<sup>1</sup> is not hydrogen;

or when R<sup>1</sup> is hydrogen, a pharmaceutically acceptable salt of the compound.

15. (Original) The pharmaceutical composition of claim 14, wherein n is 1; q is 0; t is 0; R<sup>3</sup> is hydrogen; and


A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.

16. (Currently amended) The pharmaceutical composition of claim 15, wherein ~~wherein~~ A is 2,6-dimethylphenyl.

17. (Currently amended) The pharmaceutical composition of claim 16, wherein the biologically active agent is ~~[4-(3-(2,6-Dimethylbenzyloxy)-phenyl)-4-hydroxybutanoic 4-~~  
(3-(2,6-Dimethylbenzyloxy)-phenyl)-4-hydroxybutanoic acid.

18. (Previously presented) The pharmaceutical composition of claim 14 in oral dosage form.

19. (Previously presented) A biologically active agent, wherein the agent is a compound of the formula:



Formula I

wherein

n is 1 or 2;

m is 0, 1, 2, 3 or 4;

q is 0 or 1;

t is 0 or 1;

R<sup>2</sup> is alkyl having from 1 to 3 carbon atoms;

R<sup>3</sup> is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or

cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or  
a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and

$R^1$  is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1,  $R^1$  is not hydrogen;

or when  $R^1$  is hydrogen, a pharmaceutically acceptable salt of the compound, wherein the agent is substantially pure.


20. (Original) The biologically active agent of claim 19, wherein n is 1; q is 0; t is 0;  $R^3$  is hydrogen; and  
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.

21. (Previously presented) The biologically active agent of claim 20, wherein wherein A is 2,6-dimethylphenyl.

22. (Original) The biologically active agent of claim 21,  
4-(3-(2,6-Dimethylbenzyloxy)-phenyl)-4-hydroxybutanoic acid.

Claim 23 (canceled).

24. (Previously presented) A biologically active agent, wherein the agent is a compound of the formula:



Formula I

wherein

n is 1 or 2;

m is 0, 1, 2, 3 or 4;

q is 0 or 1;

t is 0 or 1;

R<sup>2</sup> is alkyl having from 1 to 3 carbon atoms;

R<sup>3</sup> is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or



a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and

$R^1$  is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1,  $R^1$  is not hydrogen;

or when  $R^1$  is hydrogen, a pharmaceutically acceptable salt of the compound, wherein the agent is present in a mammal other than a mouse.

25. (Previously presented) The biologically active agent of claim 24, wherein n is 1; q is 0; t is 0;  $R^3$  is hydrogen; and

A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.

26. (Currently amended) The biologically active agent of claim 25, wherein ~~wherein~~ A is 2,6-dimethylphenyl.

27. (Previously presented) The biologically active agent of claim 26, 4-(3-(2,6-Dimethylbenzyloxy)-phenyl)-4-hydroxybutanoic acid.

28. (Previously presented) The biologically active agent of claim 27, wherein the mammal is a human.

29. (Previously presented) The biologically active agent of claim 24, wherein the mammal is a human.